Drug Profile
Research programme: neuropeptide Y 5 receptor antagonists - Synaptic Pharmaceuticals
Latest Information Update: 20 Aug 2007
Price :
$50
*
At a glance
- Originator Lundbeck Research USA
- Class
- Mechanism of Action Neuropeptide Y5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 02 Sep 1999 Preclinical development for Obesity in USA (Unknown route)